Journal of Biomaterials Science Polymer Edition,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 20
Published: Oct. 16, 2024
Nanoscale
drug
delivery
systems
that
are
both
multifunctional
and
targeted
have
been
developed
using
proteins
as
a
basis,
thanks
to
their
attractive
biomacromolecule
properties.
A
novel
nanocarrier,
aptamer
(AS1411)-conjugated
β-lactoglobulin/poly-l-lysine
(BLG/Ap/PL)
nanoparticles,
was
in
this
study.
To
unique
formulation,
the
as-prepared
nanocarrier
blends
distinctive
features
of
an
chemotherapeutic
targeting
agent
with
those
protein
nanocarriers.
By
loading
cabazitaxel
(CTX)
onto
nanocarriers,
therapeutic
potential
BLG/Ap/PL
could
be
demonstrated.
The
CTX-loaded
(CTX@BLG/Ap/PL)
showed
regulated
release
profile
acidic
milieu,
which
improve
efficacy
cancer
cells
high
encapsulation
up
93%.
However,
compared
free
CTX,
CTX@BLG/Ap/PL
killed
colorectal
HCT116
higher
at
24
48
h.
Further
investigation
confirms
apoptosis
by
acridine
orange
ethidium
bromide
(AO/EB),
DAPI
staining
morphological
changes,
chromatin
condensation,
membrane
blebbing
treated
cell
through
flow
cytometry
displayed
percentages
apoptosis.
Cell
cycle
analysis
revealed
induced
sub-G1
G2/M
phase
(apoptosis)
Annexin
V/propidium
iodide
(PI)
confirmed
induces
cells.
Overall,
study
proved
had
several
advantages
over
drugs
promise
solution
clinical
problems
associated
antitumor
systems.
Journal of Controlled Release,
Journal Year:
2024,
Volume and Issue:
368, P. 703 - 727
Published: March 19, 2024
Drug
delivery
platforms
have
gracefully
emerged
as
an
indispensable
component
of
novel
cancer
chemotherapy,
bestowing
targeted
drug
distribution,
elevating
therapeutic
effects,
and
reducing
the
burden
unwanted
side
effects.
In
this
context,
hybrid
systems
artfully
harnessing
virtues
liposomes
hydrogels
bring
remarkable
benefits,
especially
for
localized
therapy,
including
intensified
stability,
excellent
amenability
to
hydrophobic
hydrophilic
medications,
controlled
liberation
behavior,
appropriate
mucoadhesion
mucopenetration
shift.
Moreover,
three-dimensional
biocompatible
liposome-integrated
hydrogel
networks
attracted
unprecedented
interest
in
tissue
regeneration,
given
their
tunable
architecture
physicochemical
properties,
well
enhanced
mechanical
support.
This
review
elucidates
presents
cutting-edge
developments
recruiting
treatment
regeneration.
Cancers,
Journal Year:
2023,
Volume and Issue:
15(21), P. 5300 - 5300
Published: Nov. 6, 2023
Ovarian
cancer
(OC)
is
the
most
common
lethal
gynecologic
cause
of
death
in
women
worldwide,
with
a
high
mortality
rate
and
increasing
incidence.
Despite
advancements
treatment,
OC
patients
still
die
from
their
disease
due
to
late-stage
diagnosis,
lack
effective
diagnostic
methods,
relapses.
Aptamers,
synthetic,
short
single-stranded
oligonucleotides,
have
emerged
as
promising
anticancer
therapeutics.
Their
ability
selectively
bind
target
molecules,
including
cancer-related
proteins
receptors,
has
revolutionized
drug
discovery
biomarker
identification.
Aptamers
offer
unique
insights
into
molecular
pathways
involved
development
progression.
Moreover,
they
show
immense
potential
delivery
systems,
enabling
targeted
therapeutic
agents
cells
while
minimizing
off-target
effects
reducing
systemic
toxicity.
In
context
OC,
integration
aptamers
non-coding
RNAs
(ncRNAs)
presents
an
opportunity
for
precise
efficient
gene
targeting.
Additionally,
conjugation
nanoparticles
allows
accurate
ncRNAs
specific
cells,
tissues,
or
organs.
this
review,
we
will
summarize
use
challenges
associated
alone
aptamer–ncRNA
conjugates,
nanoparticles,
multivalent
aptamer-based
therapeutics
treatment
OC.
International Journal of Nanomedicine,
Journal Year:
2025,
Volume and Issue:
Volume 20, P. 3493 - 3525
Published: March 1, 2025
Human
serum
albumin
(HSA)
has
emerged
as
a
promising
carrier
for
nanodrug
delivery,
offering
unique
structural
properties
that
can
be
engineered
to
overcome
key
challenges
in
cancer
treatment,
especially
resistance
chemotherapy.
This
review
focuses
on
the
cellular
uptake
of
albumin-based
nanoparticles
and
modifications
enhance
their
ability
bypass
mechanisms,
particularly
multidrug
type
1
(MDR1),
by
improving
targeting
cells.
In
our
approach,
we
integrate
chemical
albumin,
its
interactions
with
cells,
surface
delivery
systems
enable
those
related
MDR1,
precisely
target
receptors
cells
improve
treatment
efficacy.
We
discuss
while
well-established
such
gp60
gp18/30
are
crucial
transcytosis,
biology
remains
underexplored,
limiting
translational
potential.
Additionally,
explore
potential
emerging
targets,
cluster
differentiation
44
(CD44),
(CD36)
transferrin
receptor
TfR1,
well
advantages
using
dimeric
forms
(dHSA)
further
resistant
Drawing
from
clinical
examples,
including
success
albumin-bound
paclitaxel
(Abraxane)
new
formulations
like
Pazenir
Fyarro
(for
Sirolimus),
identify
gaps
current
knowledge
propose
strategies
optimize
systems.
conclusion,
nanoparticles,
when
tailored
appropriate
modifications,
have
By
enhancing
albumin's
efficiently
deliver
therapeutic
agents,
these
carriers
represent
approach
addressing
one
oncology's
most
persistent
challenges,
substantial
outcomes.
ACS Nano,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 12, 2024
Chemoresistance
remains
a
long-standing
challenge
after
cancer
treatment.
Over
the
last
two
decades,
RNA
interference
(RNAi)
has
emerged
as
gene
therapy
modality
to
sensitize
cells
chemotherapy.
However,
use
of
RNAi,
specifically
small-interfering
(siRNA),
is
hindered
by
biological
barriers
that
limit
its
intracellular
delivery.
Nanoparticles
can
overcome
these
protecting
siRNA
in
physiological
environments
and
facilitating
delivery
cells.
In
this
review,
we
discuss
development
nanomaterials
for
therapy,
current
challenges,
future
perspectives
their
implementation
chemoresistance.
